{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:27:07Z","timestamp":1789453627021,"version":"build-2803163510"},"reference-count":51,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2017,3,30]],"date-time":"2017-03-30T00:00:00Z","timestamp":1490832000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>The approval of psychotropic drugs with novel mechanisms of action has been rare in recent years. To address this issue, further analysis of the pathophysiology of neuropsychiatric disorders is essential for identifying new pharmacological targets for psychotropic medications. In this report, we detail drug candidates being examined as treatments for psychiatric disorders. Particular emphasis is placed on agents with novel mechanisms of action that are being tested as therapies for depression, schizophrenia, or Alzheimer\u2019s disease. All of the compounds considered were recently approved for human use or are in advanced clinical trials. Drugs included here are new antipsychotic medications endowed with a preferential affinity at dopamine D3 receptor (cariprazine) or at glutamatergic or cannabinoid receptors, as well as vortioxetine, a drug approved for managing the cognitive deficits associated with major depression. New mechanistic approaches for the treatment of depression include intravenous ketamine or esketamine or intranasal esketamine. As for Alzheimer\u2019s disease, the possible value of passive immunotherapy with agents such as aducanumab is considered to be a potential disease-modifying approach that could slow or halt the progressive decline associated with this devastating disorder.<\/ns4:p>","DOI":"10.12688\/f1000research.10233.1","type":"journal-article","created":{"date-parts":[[2017,3,30]],"date-time":"2017-03-30T04:42:53Z","timestamp":1490848973000},"page":"397","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["New drugs in psychiatry: focus on new pharmacological targets"],"prefix":"10.12688","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9867-6054","authenticated-orcid":false,"given":"Filippo","family":"Caraci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Marco","family":"Leggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Salomone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2887-5223","authenticated-orcid":false,"given":"Filippo","family":"Drago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2017,3,30]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"599-656","DOI":"10.1016\/j.euroneuro.2015.01.016","article-title":"Learning from the past and looking to the future: Emerging perspectives for improving the treatment of psychiatric disorders.","volume":"25","author":"M Millan","year":"2015","journal-title":"Eur Neuropsychopharmacol."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"521-32","DOI":"10.1038\/nrd2094","article-title":"Drug development for CNS disorders: strategies for balancing risk and reducing attrition.","volume":"6","author":"M Pangalos","year":"2007","journal-title":"Nat Rev Drug Discov."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"1-2","DOI":"10.1038\/nrd.2016.205","article-title":"Defining the brain circuits involved in psychiatric disorders: IMI-NEWMEDS.","volume":"16","author":"F Artigas","year":"2016","journal-title":"Nat Rev Drug Discov."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"485-515","DOI":"10.1038\/nrd.2016.28","article-title":"Altering the course of schizophrenia: progress and perspectives.","volume":"15","author":"M Millan","year":"2016","journal-title":"Nat Rev Drug Discov."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"921-36","DOI":"10.1517\/14656566.2016.1149164","article-title":"Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries.","volume":"17","author":"R Garay","year":"2016","journal-title":"Expert Opin Pharmacother."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"97-115","DOI":"10.1177\/0269881114563634","article-title":"Glutamate and dopamine in schizophrenia: an update for the 21st century.","volume":"29","author":"O Howes","year":"2015","journal-title":"J Psychopharmacol."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"1781-1791","DOI":"10.1038\/npp.2011.65","article-title":"Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis.","volume":"36","author":"C de la Fuente-Sandoval","year":"2011","journal-title":"Neuropsychopharmacology."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"754-62","DOI":"10.1016\/j.biopsych.2015.03.016","article-title":"Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2\/3 receptor agonist pomaglumetad methionil in schizophrenia.","volume":"78","author":"B Kinon","year":"2015","journal-title":"Biol Psychiatry."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"711-25","DOI":"10.1007\/s00213-013-3005-0","article-title":"The antipsychotic-like effects of the mGlu group III orthosteric agonist, LSP1-2111, involves 5-HT1A signalling.","volume":"227","author":"J Wiero\u0144ska","year":"2013","journal-title":"Psychopharmacology (Berl)."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"61-69","DOI":"10.1016\/0165-6147(92)90025-2","article-title":"Molecular biology of dopamine receptors.","volume":"13","author":"D Sibley","year":"1992","journal-title":"Trends Pharmacol Sci."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"437-467","DOI":"10.1146\/annurev.pharmtox.42.091101.144224","article-title":"The binding site of aminergic G protein-coupled receptors: the transmembrane segments and second extracellular loop.","volume":"42","author":"L Shi","year":"2002","journal-title":"Annu Rev Pharmacol Toxicol."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"164-77","DOI":"10.1016\/j.pharmthera.2016.06.007","article-title":"Current drug treatments targeting dopamine D3 receptor.","volume":"165","author":"G Leggio","year":"2016","journal-title":"Pharmacol Ther."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"97-110","DOI":"10.1358\/dot.2016.52.2.2461868","article-title":"Cariprazine:New dopamine biased agonist for neuropsychiatric disorders.","volume":"52","author":"P De Deurwaerd\u00e8re","year":"2016","journal-title":"Drugs Today (Barc)."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"208-224","DOI":"10.1016\/j.euroneuro.2015.12.020","article-title":"The dopamine D3-preferring D2\/D3 dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia.","volume":"26","author":"D Watson","year":"2016","journal-title":"Eur Neuropsychopharmacol."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"315-328","DOI":"10.1007\/s00213-008-1240-6","article-title":"Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors.","volume":"202","author":"T Nagai","year":"2009","journal-title":"Psychopharmacology (Berl)."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"3-14","DOI":"10.1016\/j.euroneuro.2015.11.016","article-title":"Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology.","volume":"26","author":"J Neill","year":"2016","journal-title":"Eur Neuropsychopharmacol."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"109-19","DOI":"10.3371\/1935-1232-10.2.109","article-title":"Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3\/D2 Receptor Partial Agonist.","volume":"10","author":"L Citrome","year":"2016","journal-title":"Clin Schizophr Relat Psychoses."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"233-8","DOI":"10.1016\/S2215-0366(14)00117-5","article-title":"Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study.","volume":"2","author":"M Di Forti","year":"2015","journal-title":"Lancet Psychiatry."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"604-12","DOI":"10.1016\/j.biopsych.2015.11.018","article-title":"Therapeutic Potential of Cannabinoids in Psychosis.","volume":"79","author":"F Leweke","year":"2016","journal-title":"Biol Psychiatry."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"e920","DOI":"10.1038\/tp.2016.195","article-title":"Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose.","volume":"6","author":"P Seeman","year":"2016","journal-title":"Transl Psychiatry."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"515-27","DOI":"10.1002\/da.22063","article-title":"Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions.","volume":"30","author":"R McIntyre","year":"2013","journal-title":"Depress Anxiety."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"1290-1298","DOI":"10.2174\/1871527315666161003170312","article-title":"Selective Serotonin Reuptake Inhibitors and Serotonin and Noradrenaline Reuptake Inhibitors Improve Cognitive Function in Partial Responders Depressed Patients: Results from a Prospective Observational Cohort Study.","volume":"15","author":"S Castellano","year":"2016","journal-title":"CNS Neurol Disord Drug Targets."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"85-92","DOI":"10.1016\/j.jad.2014.09.018","article-title":"Cognitive function after clinical remission in patients with melancholic and non-melancholic depression: a 6 month follow-up study.","volume":"171","author":"M Roca","year":"2015","journal-title":"J Affect Disor."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"1433-1442","DOI":"10.1017\/S1461145712001605","article-title":"Multi-modality: a new approach for the treatment of major depressive disorder.","volume":"16","author":"E Richelson","year":"2013","journal-title":"Int J Neuropsychopharmacol."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"979-93","DOI":"10.1016\/j.euroneuro.2016.03.007","article-title":"A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults.","volume":"26","author":"M Thase","year":"2016","journal-title":"Eur Neuropsychopharmacol."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"2318-2325","DOI":"10.1016\/j.euroneuro.2015.08.019","article-title":"A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature.","volume":"25","author":"J Zohar","year":"2015","journal-title":"Eur Neuropsychopharmacol."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"155-63","DOI":"10.4306\/pi.2015.12.2.155","article-title":"Vilazodone for the treatment of major depressive disorder: focusing on its clinical studies and mechanism of action.","volume":"12","author":"S Wang","year":"2015","journal-title":"Psychiatry Investig."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"1291-304","DOI":"10.1517\/14740338.2015.1046836","article-title":"Vortioxetine : a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder.","volume":"14","author":"M Al-Sukhni","year":"2015","journal-title":"Expert Opin Drug Saf."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"43-57","DOI":"10.1016\/j.pharmthera.2014.07.001","article-title":"Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data.","volume":"145","author":"C Sanchez","year":"2015","journal-title":"Pharmacol Ther."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"70-82","DOI":"10.1016\/j.pbb.2015.05.013","article-title":"Reversal of age-associated cognitive deficits is accompanied by increased plasticity-related gene expression after chronic antidepressant administration in middle-aged mice.","volume":"135","author":"Y Li","year":"2015","journal-title":"Pharmacol Biochem Behav."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"351-66","DOI":"10.1185\/03007995.2015.1128404","article-title":"Efficacy and tolerability of switching therapy to vortioxetine versus other antidepressants in patients with major depressive disorder.","volume":"32","author":"M Brignone","year":"2016","journal-title":"Curr Med Res Opin."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"207-9","DOI":"10.1002\/wps.20058","article-title":"Neurobiological advances identify novel antidepressant targets.","volume":"12","author":"R Duman","year":"2013","journal-title":"World Psychiatry."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"218-24","DOI":"10.1016\/j.pnpbp.2015.01.002","article-title":"Has psychiatry tamed the \"ketamine tiger?\" Considerations on its use for depression and anxiety.","volume":"64","author":"K Rasmussen","year":"2016","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"259-67","DOI":"10.1038\/npp.2014.261","article-title":"Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders?","volume":"40","author":"G Sanacora","year":"2015","journal-title":"Neuropsychopharmacology."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"698-710","DOI":"10.1002\/da.22505","article-title":"Ketamine For Treatment-Resistant Unipolar And Bipolar Major Depression: Critical Review And Implications For Clinical Practice.","volume":"33","author":"W Bobo","year":"2016","journal-title":"Depress Anxiety."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"816-26","DOI":"10.1176\/appi.ajp.2016.16010037","article-title":"A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.","volume":"173","author":"J Singh","year":"2016","journal-title":"Am J Psychiatry."},{"key":"ref-37","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/s12864-016-2713-3","article-title":"Molecular profile of dissociative drug ketamine in relation to its rapid antidepressant action.","volume":"17","author":"J Ficek","year":"2016","journal-title":"BMC Genomics."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"970-6","DOI":"10.1016\/j.biopsych.2014.03.026","article-title":"A randomized controlled trial of intranasal ketamine in major depressive disorder.","volume":"76","author":"K Lapidus","year":"2014","journal-title":"Biol Psychiatry."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"873-83","DOI":"10.1080\/17460441.2016.1213234","article-title":"Glutamate-Based Drug Discovery for Novel Antidepressants.","volume":"11","author":"A Pa\u0142ucha-Poniewiera","year":"2016","journal-title":"Expert Opin Drug Discov."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"245-55","DOI":"10.1038\/nrneurol.2009.39","article-title":"Management of agitation and aggression associated with Alzheimer disease.","volume":"5","author":"C Ballard","year":"2009","journal-title":"Nat Rev Neurol."},{"key":"ref-41","doi-asserted-by":"publisher","first-page":"595-608","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer's disease at 25 years.","volume":"8","author":"D Selkoe","year":"2016","journal-title":"EMBO Mol Med."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"504-17","DOI":"10.1111\/j.1365-2125.2011.04134.x","article-title":"New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs.","volume":"73","author":"S Salomone","year":"2012","journal-title":"Br J ClinPharmacol."},{"key":"ref-43","doi-asserted-by":"publisher","first-page":"270-9","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.","volume":"7","author":"M Albert","year":"2011","journal-title":"Alzheimers Dement."},{"key":"ref-44","doi-asserted-by":"publisher","first-page":"173-86","DOI":"10.2174\/18715273113129990103","article-title":"Searching for disease-modifying drugs in AD: can we combine neuropsychological tools with biological markers?","volume":"13","author":"F Caraci","year":"2014","journal-title":"CNS Neurol Disord Drug Targets."},{"key":"ref-45","doi-asserted-by":"publisher","first-page":"34-8","DOI":"10.1159\/000440842","article-title":"Tau Immunotherapy.","volume":"16","author":"E Sigurdsson","year":"2016","journal-title":"Neurodegener Dis."},{"key":"ref-46","doi-asserted-by":"publisher","first-page":"1162-76","DOI":"10.1016\/j.neuron.2014.12.064","article-title":"Immunotherapeutic approaches for Alzheimer's disease.","volume":"85","author":"T Wisniewski","year":"2015","journal-title":"Neuron."},{"key":"ref-47","doi-asserted-by":"publisher","DOI":"10.3410\/f.718248469.793494011","article-title":"F1000Prime Recommendation of [Doody RS et al., N Engl J Med 2014, 370(4): 311\u201321]","author":"X Shifu","year":"2014","journal-title":"F1000Prime."},{"key":"ref-48","doi-asserted-by":"publisher","first-page":"110-20","DOI":"10.1016\/j.jalz.2015.06.1893","article-title":"Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients.","volume":"12","author":"E Siemers","year":"2016","journal-title":"Alzheimers Dement."},{"key":"ref-49","doi-asserted-by":"publisher","first-page":"50-6","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer's disease.","volume":"537","author":"J Sevigny","year":"2016","journal-title":"Nature."},{"key":"ref-50","doi-asserted-by":"publisher","first-page":"10582-10587","DOI":"10.1523\/JNEUROSCI.1736-09.2009","article-title":"Beta-amyloid monomers are neuroprotective.","volume":"29","author":"M Giuffrida","year":"2009","journal-title":"J Neurosci."},{"key":"ref-51","article-title":"F1000Prime Recommendations, Dissents and Comments for [SevignyJ et al., Nature 2016, 537: 50\u20136].","year":"2016","journal-title":"F1000Prime."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/6-397\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/6-397\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/6-397\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T11:16:29Z","timestamp":1553253389000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/6-397\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,30]]},"references-count":51,"URL":"https:\/\/doi.org\/10.12688\/f1000research.10233.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.11022.r19542","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.11022.r19544","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.11022.r19545","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,30]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/6-397\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.11022.r19542, S. J. Enna, Research and Graduate Education, Department of Physiology and Pharmacology, Kansas University Medical Center, Kansas City, KS, USA, 30 Mar 2017, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/6-397\/v1#referee-response-19542","order":0,"name":"referee-response-19542","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.11022.r19545, Philippe De Deurwaerd\u00e8re, CNRS, Institut des Maladies Neurod\u00e9g\u00e9n\u00e9ratives, Bordeaux, France, 30 Mar 2017, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/6-397\/v1#referee-response-19545","order":1,"name":"referee-response-19545","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.11022.r19544, Andrzej Pilc, Michal Korostynski, Department of Neurobiology, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland, 30 Mar 2017, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/6-397\/v1#referee-response-19544","order":2,"name":"referee-response-19544","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":3,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}